WO2020220092A1 - Compositions et procédés pour le soulagement de la douleur et de l'anxiété - Google Patents

Compositions et procédés pour le soulagement de la douleur et de l'anxiété Download PDF

Info

Publication number
WO2020220092A1
WO2020220092A1 PCT/AU2020/050436 AU2020050436W WO2020220092A1 WO 2020220092 A1 WO2020220092 A1 WO 2020220092A1 AU 2020050436 W AU2020050436 W AU 2020050436W WO 2020220092 A1 WO2020220092 A1 WO 2020220092A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
oil
pain
anxiety
glyceryl
Prior art date
Application number
PCT/AU2020/050436
Other languages
English (en)
Inventor
Philip Madden
Original Assignee
Cannadol Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019901486A external-priority patent/AU2019901486A0/en
Application filed by Cannadol Pharmaceuticals filed Critical Cannadol Pharmaceuticals
Priority to AU2020264426A priority Critical patent/AU2020264426A1/en
Publication of WO2020220092A1 publication Critical patent/WO2020220092A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to the use of compositions comprising cannabinoids for the treatment or alleviation of pain in patients in need thereof.
  • the present invention also relates to the use of compositions comprising cannabinoids for the treatment or alleviation of anxiety in patients in need thereof.
  • the compositions may comprise mixtures of cannabinoids and appropriate terpenes.
  • the invention relates to the use of controlled amounts of D-9 Tetra Hydra Cannabinol (D9 THC) cannabinoids in compositions for the indications discussed herein.
  • D9 THC Tetra Hydra Cannabinol
  • Cannabis sativa L. produces more than 60 terpeno-phenols that are not found in any other plant. Many of these compounds are thought to be of medical importance.
  • a 9 -tetrahydrocannabinol (Gaoni & Mechoulam, 1964) is an important member of this group and has been the subject of research for many years.
  • D 9 -THO is known as the major psychoactive component obtainable from cannabis products, and as such, is often less favoured as a compound of interest by medical researchers.
  • Other components of cannabis are not known to be psychoactive, and have been extensively researched for their medical properties.
  • Cannabidiol CBD
  • CBD Cannabidiol
  • Another compound Cannabichromene (CBC)
  • CBC Cannabichromene
  • the acid forms of cannabinoids are precursors of the neutral cannabinoids. These, such as THC acid and CBD acid, have been found by investigators to be antibiotic and have previously shown utility in veterinary medicine.
  • Endocannabinoids are cannabinoids naturally occurring in the human body. These compounds include the well-known anandamide and 2-arachidonoyl glycerol, and have been found to be involved in the regulation of the immune, cardiovascular, reproductive, respiratory, skeletal and central nervous systems of the human body. The appear to target the CB1/CB2 receptors amongst others (Howlett et ai, 2002), and it is thought that the plant cannabinoids may be able to bind and influence the same receptors.
  • CBD cannabinoids
  • CBD administered alone has been found to have antipsychotic effects as efficacious as standard anti-psychotic drugs but with fewer side effects. It also has shown impressive efficacy in treating intractable childhood epilepsy that cannot be treated with conventional anti-convulsants.
  • THC is known to be the principal psychoactive constituent of cannabis and is one of only three cannabinoids scheduled by the UN Convention on Psychotropic Substances listed under Schedule II, less interest has been placed onto this substance in relation to its medical uses.
  • Dronabinol a synthetic form of THC for use as an appetite stimulant in AIDS patients and as an antiemetic during chemotherapy, has been approved by the US FDA and is available on prescription in the United States, Canada, Germany, and New Zealand.
  • Traditional pain relief medication includes medicines that can be bought without prescription, including paracetamol, ibuprofen and aspirin. However, these medications are known to have potential side effects which vary amongst individuals, such as those with allergies, chronic illness or that are on any other medicines.
  • Paracetamol for example Panadol and Panamax
  • side effects of its use include serious liver damage if taken in high doses.
  • Non-steroidal anti-inflammatory (NSAIDs) drugs such as ibuprofen
  • NSAIDs are another such non-prescription medication, which are effective against mild to moderate pain.
  • NSAIDs have the potential of serious side-effects and may not be suitable for people with stomach troubles, heart problems, kidney impairment, high blood pressure or asthma.
  • Oral NSAIDs are not recommended for older people. Again, with NSAIDS, overdosing can be dangerous.
  • codeine is a type of prescription-only opioid agent related to morphine. Codeine and codeine-containing medicines are may carry with them the potential for severe side effects if abused, and may induce dependency.
  • Morphine and morphine-like drugs are strong painkillers. They can come in different formulations such as tablets, capsules and patches and will only be prescribed after consultation with a doctor or a pain specialist as part of a long-term plan to manage pain. The dose and response will be closely monitored.
  • Cannabinoids have shown significant promise in basic experiments on pain. Cannabinoids appear to block peripheral nerve pain in experimental animals due to directly targeting cannabinoid receptors on peripheral nerves. Research also appears to suggest that opiates and cannabinoids use different pathways to treat pain, which could lead to the addition of cannabis-based medicines to opiates to increase their efficacy while limiting their side effects.
  • Antidepressants can improve mood, but they do not provide a long-term solution. Side effects are often experienced, and the risks and benefits must be considered. Common side effects of antidepressant medication can include nausea, headaches, anxiety, sweating, dizziness, agitation, weight gain, dry mouth and sexual difficulties.
  • cannabis-based medicaments can alter mood, perception and motivation. Unregulated or high doses of cannabis have reportedly led to undesirable reactions, such as anxiety, panic or hallucinations, and may lead to impairment of cognitive functions, perception, reaction time, learning and memory.
  • compositions of the invention have been found to effectively treat pain and anxiety whilst at the same time do not lead to psychoactive effects, impairment of cognitive functions, perception, reaction time, learning or memory.
  • the compositions of the invention are therefore useful alternatives to the traditional medications currently available in the art for such indications.
  • compositions for use in the treatment of pain or anxiety comprising D 9 - tetrahydrocannabinol (A 9 -THC) and optionally a pharmaceutically acceptable carrier or excipient.
  • the composition may further comprise one or more additional cannabinoid.
  • additional cannabinoid optionally selected from the group consisting of THCA (tetrahydrocannabinolic acid), CBD (cannabidiol), CBDA (cannabidiolic acid), CBN (cannabinol), CBG (cannabigerol), CBC (cannabichromene), CBCA (cannabichromenic acid), CBL (cannabicyclol), CBV (cannabivarin), THCV (tetrahydrocannabivarin), CBDV (cannabidivarin), CBCV (cannabichromevarin), CBGV (cannabigerovarin), CBGM (cannabigerol monomethyl ether), CBE (cannabielsoin) and CBT (cannabicitran).
  • said one or more further cannabinoid is selected from the group consisting of CBD and CBG, most preferably CBD.
  • the A 9 -THC is present in the composition at at least 0.01 , 0.015, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.055, 0.06, 0.065, 0.07, 0.075, 0.08, 0.085, 0.09, 0.095, 0.100, 0.105, 0.110, 0.115, 0.120, 0.130, 0.135, 0.140, 0.145, 0.150, 0.155, 0.160, 0.165, 0.170, 0.175, 0.180, 0.185, 0.190, 0.195, 0.200, 0.205, 0.210,
  • the A9-THC is present in the composition at about 0.120-0.150 percent by volume.
  • the A9-THC-acid is present in the composition at about 0.010, 0.015, 0.020, 0.025, 0.030, 0.035, 0.040, 0.045, 0.050, 0.055, 0.060, 0.065, 0.070,
  • the A 9 -THC acid is present in the composition at about 0.050-0.100 percent by volume.
  • the composition further comprises one or more terpene, selected from the group consisting of a pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, beta-amyrin, thujone, citronellol, pulegone, 1 ,8-cineole and cycloartenol.
  • a pinene limonene
  • linalool caryophyllene
  • caryophyllene oxide caryophyllene oxide
  • myrcene humulene
  • borneol eucalyptol
  • terpineol nerolidol
  • phytol geraniol
  • bisabolol camphene
  • suitable terpenes may be preferably selected from the group consisting of a-Pinene and b-Pinene.
  • a-Pinene is present in the compositions at about 0.100, 0.105, 0.1 10, 0.1 15, 0.120, 0.130, 0.135, 0.140, 0.145, 0.150, 0.155, 0.160, 0.165, 0.170, 0.175, 0.180, 0.185, 0.190, 0.195, 0.200, 0.205, 0.210, 0.215, 0.220, 0.225, 0.230, 0.235, 0.240, 0.245, 0.250, 0.255, 0.260, 0.265, 0.270, 0.275, 0.280, 0.285, 0.290 or 0.300, 0.305, 0.310, 0.315, 0.320, 0.325, 0.330, 0.335, 0.340, 0.345, 0.350, 0.355, 0.360, 0.365, 0.370, 0.375, 0.380, 0.385, 0.390 or 0.400 percent by volume.
  • a-Pinene is present at about 0.20-0.30 percent by volume.
  • b-Pinene is present in the compositions at about
  • b-Pinene is present in the compositions at about 0.050-0.100 percent by volume.
  • the present invention relates to a composition for treating a disorder selected from the group consisting of pain and anxiety, said composition comprising:
  • compositions of the invention may be formulated for sublingual or buccal delivery.
  • compositions may be formulated for parenteral delivery.
  • the composition is formulated for oral delivery.
  • the composition is formulated as a spray.
  • the composition is formulated as a solid dosage form, such as a gel capsule or a tablet.
  • the composition may also be formulated as a cream, an ointment, a gel, a paste, a powder, a medical patch, a cigarette, a vaporizer liquid or is prepared as a liquid suitable for parenteral administration.
  • the excipient may comprise a solvent.
  • the solvent is an oil.
  • the solvent comprises an alcohol.
  • the composition may be formulated as a solution comprising a pharmaceutically effective amount of a cannabinoid of the invention, and optionally a terpene, dispersed in a pharmaceutically acceptable oil-based carrier; and a hard gelatin capsule encapsulating the mixture of the cannabinoid and the oil- based carrier.
  • said oil-based carrier may be a triglyceride selected from the group consisting of almond oil; babassu oil; borage oil; blackcurrant seed oil; canola oil; castor oil; coconut oil; corn oil; cottonseed oil; evening primrose oil; grapeseed oil; groundnut oil; mustard seed oil; olive oil; palm oil; palm kernel oil; peanut oil; rapeseed oil; safflower oil; sesame oil; shark liver oil; soybean oil; sunflower oil; hydrogenated castor oil; hydrogenated coconut oil; hydrogenated palm oil; hydrogenated soybean oil; hydrogenated vegetable oil; hydrogenated cottonseed and castor oil; partially hydrogenated soybean oil; soy oil; glyceryl tricaproate; glyceryl tricaprylate; glyceryl tricaprate; glyceryl triundecanoate; glyceryl trilaurate; glyceryl trioleate; glyceryl trilinoleate
  • the composition additionally contains an additive selected from the group consisting of antioxidants, emulsifiers and texturizers vegetable oils, plant extracts, honey, sucrose, glucose and fructose, pharmaceutical excipients and combinations thereof.
  • an additive selected from the group consisting of antioxidants, emulsifiers and texturizers vegetable oils, plant extracts, honey, sucrose, glucose and fructose, pharmaceutical excipients and combinations thereof.
  • the present invention provides a method of treating pain in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a composition according to the invention.
  • the pain treated by the present invention includes pain resulting from inflammation, including inflammation from multiple sclerosis, Alzheimer disease, Parkinson disease motor neurone disease and traumatic brain injury.
  • the pain may be acute and/or chronic pain including chronic pain from motor neurone disease, multiple sclerosis, Fibromyalgia, cancer and peripheral neuropathy.
  • the present invention provides a method for producing a composition of the invention, comprising providing at least A9-THC and blending it with a terpene.
  • the method includes extracting cannabis plant material to form an extract.
  • extracting comprises contacting said cannabis plant material with an extractant to form an extract, and said extractant comprises at least A9-THC.
  • the method comprises synthesizing at least D9- THC and blending said synthesized cannabinoid with a terpene.
  • the method comprises blending cannabis plant material with said terpene.
  • the method comprises administering a dose of the composition of 5 mg/kg/day and increased by 2 to 5 mg/kg increments to a maximum dose of 20 mg/kg/day.
  • the invention provides a method of treating anxiety in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a composition according to the invention.
  • the anxiety treated by the compositions of the invention is related to a patient having a terminal disease, or having a chronic disease.
  • the anxiety may be generalised anxiety disorder.
  • the anxiety may be selected from the group consisting of social anxiety, one or more specific phobias, panic disorder, obsessive compulsive disorder, and post-traumatic stress disorder.
  • the composition is administered at a dose of 5 mg/kg/day and increased by 2 to 5 mg/kg increments to a maximum dose of 20 mg/kg/day.
  • the treatment involves administering a plurality of compositions comprising one or more cannabinoids of the invention, wherein said plurality of compositions are administered separately, sequentially or simultaneously to one another, and wherein at least one of the compositions comprises D9 THC.
  • the present invention provides a product comprising tablets, gel capsules, medical patches, cigarettes and vaporizer liquids containing the composition of the invention.
  • the invention provides a use of a therapeutically effective amount of a composition according to the invention for the manufacture of a medicament for treating pain in a subject.
  • the invention provides a use of a therapeutically effective amount of a composition according to the invention for the manufacture of a medicament for treating anxiety in a subject.
  • the invention also provides a composition according to the invention for use as a medicament.
  • the invention also provides a composition according to the invention for treating pain in a subject.
  • the invention provides a composition according to the invention for treating anxiety in a subject.
  • weight ratio means the ratio between weight content, e.g. in an aqueous solution containing 20% solute and 80% water, the solute to water weight ratio is 20:80 or 1 :4.
  • the term“about” can mean within 1 or more standard deviation per the practice in the art. Alternatively,“about” can mean a range of up to 20%, up to 10%, or up to 5%. In certain embodiments,“about” can mean to 5%. When particular values are provided in the specification and claims the meaning of “about” should be assumed to be within an acceptable error range for that particular value.
  • said composition comprises at least two cannabinoids, at least three, at least four or at least five.
  • Cannabinoids have an acid form as known in the art, and a non-acid form (which is also referred to as decarboxylated form, since it can be generated by decarboxylating the acid form).
  • the acid form may be indicated herein by the letter (a) at the end of the cannabinoid acronym, e.g. tetrahydrocannabiniolic acid is indicated as THCa, while the decarboxylated form is THC.
  • the acid form may also be indicated herein by the use of the word“acid”, such as THC acid.
  • said cannabinoids are selected from the group consisting of THCa or THC, CBCa or CBC, CBDa or CBD, CBGa or CBG, THCVa or THCV, CBDVa or CBDV and CBNa or CBN.
  • At least one of said cannabinoids may be in acid form. In one embodiment, at least one of said cannabinoids is at least partially in decarboxylated form.
  • said composition comprises both CBD and/or CBDa and THC and/or THCa and the weight/weight ratio between THC and/or THCa and CBD and/or CBDa ((THC+THCa) / (CBD+CBDa)) is at least 10, at least 15, at least 20, at least 25 or at least 30.
  • the composition of the invention may comprise a carrier at least at 5%, 10%, 15%, 20%, 25%, 30%, 35% or 40% by volume.
  • the carrier in some embodiments is selected from the group consisting of vegetable oils, such as olive oil, coconut oil or sesame oil, honey, bees wax, cellulose or pharmaceutical excipients, and combinations thereof.
  • vegetable oils such as olive oil, coconut oil or sesame oil, honey, bees wax, cellulose or pharmaceutical excipients, and combinations thereof.
  • cellulose refers to cellulose, hemicellulose and their combinations.
  • the composition is used in treatment against pain and or anxiety, especially resulting from motor neurone disease, rheumatoid arthritis or Crohn's Disease, sarcoidosis, asthma, Alzheimers disease, multiple sclerosis, psoriasis, ulcerative colitis, osteoarthritis or spondyloarthropathy (erg. ankylosing spondylitis), and pain and or anxiety resulting from terminal disease.
  • motor neurone disease especially resulting from motor neurone disease, rheumatoid arthritis or Crohn's Disease, sarcoidosis, asthma, Alzheimers disease, multiple sclerosis, psoriasis, ulcerative colitis, osteoarthritis or spondyloarthropathy (erg. ankylosing spondylitis), and pain and or anxiety resulting from terminal disease.
  • the patient is preferably a mammal such as a human.
  • the term“active ingredient” as used herein is used interchangeably with the term “active agent” and refers to an agent or a mixture of agents that causes a desired therapeutic effect.
  • the active ingredient is a cannabinoid and/or a terpene.
  • the term“cannabinoid” as used herein means chemical compounds of a class able to act on cannabinoid receptors in cells that alter neurotransmitter release in the brain.
  • Cannabinoids may be endocannabinoids (produced in the body of animals), phytocannabinoids (produced in cannabis and some other plants), and synthetically manufactured cannabinoids.
  • Cannabinoids useful in the compositions of the invention comprise one or more cannabinoid selected from the following group consisting of:
  • THC tetrahydrocannabinol
  • THCA tetrahydrocannabinolic acid
  • CBD canannabidiol
  • CBDA canannabidiolic acid
  • CBN canannabinol
  • CBG canannabigerol
  • CBC cannabichromene
  • CBL cannabicyclol
  • CBV cannabivarin
  • THCV tetrahydrocannabivarin
  • CBDV canbidivarin
  • CBCV canbichromevarin
  • CBGV canbigerovarin
  • CBGM canannabigerol monomethyl ether
  • CBE cannabielsoin
  • CBT canannabicitran
  • Tetrahydrocannabinol is the primary psychoactive component of the Cannabis plant. Forms include Delta-9-tetrahydrocannabinol (A9-THC, THC) and delta-8- tetrahydrocannabinol (Dd-THC). These cannabinoids bind to the CB1 cannabinoid receptors in the brain.
  • Cannabidiol is a non-psychotropic cannabinoid. Cannabidiol does not bind strongly to CB1 and CB2 receptors but appears to act as an indirect antagonist of cannabinoid agonists. CBD is though to be an antagonist of the GPR55 receptor, expressed in the caudate nucleus and putamen. Cannabidiol is however an agonist of the 5-HT1 A receptor. CBD may inhibit with the uptake of adenosine, and may play a role in promoting sleep and suppressing arousal. CBD may prevent the short-term memory loss associated with THC.
  • CBD has shown promise as a treatment for chronic pain, and is currently used as a topical oil treatment.
  • Cannabinol is produced by THC degradation, but is only mildly psychoactive. It has higher affinity to the CB2 receptor than the CB1 receptor.
  • Cannabigerol is thought to be non-psychoactive. CBG binds to the CB2 receptor and has been shown in animal studies to promote apoptosis in cancer cells and lead to inhibition of tumour growth. CBG is an agonist of a2-adrenergic receptor, and is a 5-HT1A and CB1 receptor antagonist.
  • THC Tetrahydrocannabivarin
  • Cannabidivarin (CBDV) is found in small quantities in cannabis, although little is known at the present date of its properties..
  • Cannabichromene is a non-psychoactive agonist of TRPV1 and TRPA1 receptors, and appears to inhibit with their ability to break down endocannabinoids. CBC has shown promising antitumor effects in animal breast cancer models.
  • Synthetic cannabinoids are compounds that have a cannabinoid or cannabinoid- like structure and are artificially manufactured using chemical means rather than produced naturally by an animal or by a plant.
  • terpene refers to a class of hydrocarbon organic compounds, produced for chemical protection by many plants and insects. Terpenes may have a strong odor and when modified to have additional functional groups are known as “terpenoids (or isoprenoids)”.
  • isolated is intended to include a naturally occurring substance that has been purified from its natural source or has been chemically synthesised.
  • compositions of the invention can be used alone or in combination with other pharmaceutically active agents.
  • other pharmaceutically active agents include, but are not limited to, anti-inflammatory agents (e.g., NSAIDS, bradykinin receptor antagonists, hormones and autacoids such as corticosteroids), anti-depressant agents, anti viral agents, antiseptic agents (e.g., antibacterials), local anaesthetics, anti-migraine agents, opioids, and other pain relieving medication.
  • the invention provides pharmaceutical compositions of any of the foregoing cannabinoids and/or terpenes.
  • Exemplary pharmaceutical compositions are formulated in a pharmaceutically acceptable carrier.
  • compositions of the invention may optionally be used alone or as part of a therapeutic regimen together with other treatments, therapies, or interventions prescribed for the particular disease, condition, injury or disorder being treated.
  • the compositions may be used together with a treatment modalities selected from the group consisting of administration of cannabinoid pharmaceuticals, chemotherapy, radiotherapy, homeopathic therapy, diet, stress management, and surgery.
  • compositions of the invention are administered to treat a particular primary disease, injury, disorder, or condition. Additionally or alternatively, the compositions of the invention may be administered to treat pain associated with a disease, injury, disorder, or condition. In other embodiments, compositions of the invention may be administered to treat symptoms secondary to the primary disease, injury, disorder, or conditions.
  • preventing is art-recognized to include administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition.
  • prevention of pain or anxiety includes, for example, reducing the degree of, or delaying, pain or anxiety sensations experienced by subjects in a treated population versus an untreated control population.
  • treating includes prophylactic and/or therapeutic treatments.
  • prophylactic or therapeutic treatment is recognized in the art and comprises administration to a subject one or more of the compositions of the invention.
  • the treatment is prophylactic if it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) as it protects the host against developing the unwanted condition.
  • the treatment is therapeutic if it is administered after manifestation of the unwanted condition, as it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof.
  • Pain may be chronic pain or acute pain. Chronic pain or acute pain differ in duration, and underlying mechanism. Chronic pain is persistent and often does not respond well to treatment with currently available analgesics, non-steroidal anti-inflammatory drugs, and opioids.
  • Neuropathic pain and cancer pain are subcategories of chronic pain known in the art (Wang and Wang (2003) Advanced Drug Delivery Reviews 55: 949-965). Neuropathic pain results from damage (e.g., from disease, injury, age) to the nervous system (e.g., nerves, spinal cord, CNS, PNS). Cancer-related pain can be related to the particular treatment regimen (e.g., radiation, chemotherapeutics, surgery) undertaken or to tumour infiltration, compression of nerves and substances secreted by tumours.
  • damage e.g., from disease, injury, age
  • the nervous system e.g., nerves, spinal cord, CNS, PNS
  • Cancer-related pain can be related to the particular treatment regimen (e.g., radiation, chemotherapeutics, surgery) undertaken or to tumour infiltration, compression of nerves and substances secreted by tumours.
  • Pain treated by the compositions of the invention may be nociceptive, inflammatory, or neuropathic.
  • Nociceptive pain is pain experienced following, for example, changes or extremes in temperature, exposure to acids, exposure to chemical agents, exposure to force, and exposure to pressure.
  • Inflammation results from the immune system's response to injury or disease and the recruitment of macrophages, mast cells, neutrophils, and other cells of the immune system.
  • cytokines and other factors e.g., histamine, serotonin, bradykinin, prostaglandins, ATP, H+, nerve growth factor, TNFa, endothelins, interleukins
  • Standard therapy for the pain of inflammation include Cox2 inhibitors and opioids.
  • Neuropathic pain results from damage (e.g., from disease, injury, age) to the nervous system- (e.g., nerves, spinal cord, CNS, PNS).
  • Tricyclic antidepressants, anticonvulsants, Na+ channel blockers, NMDA receptor antagonists, and opioids are useful in the treatment of neuropathic pain.
  • Pain is typically studied in one of many animal models understood by those with skill in the present art. Such models use a variety of agents or procedures to simulate pain resulting from injuries, diseases, or other conditions (Blackburn-Munro (2004) Trends in Pharmacological Sciences 25: 299-305). Compounds or procedures that are found to reduce pain in the animals can be advance for further research in humans using procedures understood by those with skill in the present art.
  • composition is intended to encompass a product comprising the specified active and optionally other (i.e. , non-active) ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • terapéuticaally effective amount means that amount of an active ingredient, or composition of the present invention that is effective for producing some desired therapeutic effect in an animal, at a reasonable benefit/risk ratio applicable to any medical treatment.
  • the term describes an amount of an active ingredient or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect desired.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable carrier means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, suitable for carrying the active ingredients of the invention.
  • Acceptable means being compatible with the other ingredients of the formulation and not harmful to the patient.
  • Potentially useful pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alg
  • Lubricants including sodium lauryl sulfate and magnesium stearate, as well as coating agents, colouring agents, release agents, sweetening, flavouring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
  • Antioxidants that are considered pharmaceutically acceptable in the present invention include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and similar antioxidents which would be understood as useful by one having skill in the present art.
  • water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
  • oil-soluble antioxidants such as ascorbyl palmitate, but
  • compositions of the present invention may be formulated for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration.
  • the formulations may be provided in unit dosage form by any methods well known to those skilled in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will change.
  • the quantity of active ingredient that can be combined with a carrier material to produce a single dosage form for the invention will usually be an amount of the active ingredient sufficient to produce a therapeutic effect.
  • compositions of the invention may be prepared by bringing into association an active ingredient of the present invention with the carrier and, optionally, one or more accessory ingredients.
  • an active ingredient of the present invention is brought into intimate association with a liquid carrier, and/or a finely divided solid carrier, and then, if necessary, the product is shaped.
  • compositions of the invention may be prepared for oral administration as capsules, pills, tablets, cachets, granules, lozenges, powders, or may be formulated as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as a syrup, bolus, electuary or paste, or a mouth wash, or an elixir, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes or other useful form known to the art, each containing a predetermined amount of an active ingredient of the present invention.
  • an inert base such as gelatin and glycerin, or sucrose and acacia
  • Pharmaceutically acceptable carriers for solid dose forms include sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato, or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants,
  • Compositions of the invention may also be formulated as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
  • Compressed or moulded tablets can be prepared with additional binder (such as, gelatin or hydroxypropyl methyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface- active or dispersing agent.
  • the solid dosage forms of the invention may optionally be provided with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical- formulating art so as to provide slow or controlled release of the active ingredient therein.
  • coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical- formulating art so as to provide slow or controlled release of the active ingredient therein. Examples include using hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
  • the invention may be formulated as a liquid dosage form for oral administration.
  • these include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs, including inert diluents known in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3- butylene glycol, oils including cottonseed, groundnut, corn, germ, olive, castor and sesame oils, glycerol, tetra hydrofury I alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents known in the art, such as, for example, water or other solvents, solubilizing agents and emulsifier
  • adjuvants can be included, such as wetting agents, emulsifying and suspending agents, sweetening, flavouring, colouring, perfuming and preservative agents.
  • Suspending agents suitable for use with suspensions of the present invention include aluminum metahydroxide, bentonite, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, tragacanth and agar-agar and mixtures thereof.
  • the invention also contemplates the administration of the compositions via catheter, stent, wire, or other intraluminal device. Administration of such devices may include administering to the bladder, urethra, ureter, rectum, or intestine.
  • compositions of the present invention can be prepared as a powder, a spray, an ointment, a paste, a cream, a lotion, a gel, a solution, a patch and an inhalant.
  • parenteral administration refers to means other than enteral and topical administration.
  • Such means may include intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
  • compositions of this invention may be formulated to comprise one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which are reconstitutable into sterile injectable solutions or dispersions before using as understood by those skilled in the art.
  • Aqueous and nonaqueous carriers useful in formulations of the compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Dosage levels of the active ingredients in the compositions of the invention will depend upon numerous factors including the particular cannabinoid(s) used, the mode and time of administration, the rate of excretion of the particular cannabinoid being used, the treatment duration, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and other factors well known in the medical arts such as whether other pharmaceutically active compounds are to be used in combination with the particular active ingredient employed.
  • the required dose can be readily determined by a physician or veterinarian of skill in the art based on the factors above.
  • the physician or veterinarian may determine the correct dose by administering a very low dose of the active ingredients followed by gradually increasing the dosage until the desired effect is achieved.
  • the dose of the active ingredient of the invention may optionally be separated into two, three, four, five, six or more sub-doses for separate administration throughout the day.
  • compositions of the present invention may be useful to treat mammals such as pets or livestock, and primates, in particular humans.
  • a“subject” is a mammal, preferably a human, but can also be an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
  • Figure 1 shows the results of HPLC analysis indicating the level of cannabinoids in a representative composition of the invention.
  • Figure 2 shows the results of GCMS analysis indicating the level of terpenes in a representative composition of the invention.
  • MND Motor Neurone Disease
  • a single-centre, 5-week (1-week run-in, 4-week treatment), randomized, double-blind, placebo-controlled, parallel-group trial is held for 20 patients having MND and central pain states (including dysesthetic and/or painful spasms) of a composition of the invention (CCC), containing delta-9-tetrahydrocannabinol:cannabidiol (THC:CBD) delivered via an oil in clear gel-capsule of 1 ml, as adjunctive analgesic treatment.
  • CCC composition of the invention
  • THC:CBD delta-9-tetrahydrocannabinol:cannabidiol
  • Each capsule delivers 0.130 percent by volume of THC, THC Acid cannabinoid at 0.05-0.1 percent by volume, alpha- pinene at 0.21% percent by volume and beta-pinene, at 0.05% percent by volume.
  • Patients can gradually self-titrate to a maximum of 12 tablets in 24 hours.
  • CCC Pain and sleep disturbance are recorded daily on an 11 -point numerical rating scale.
  • the CCC is superior to placebo in reducing the mean intensity of pain at a 95% Cl and sleep disturbance at a 95% Cl: CCC is generally well tolerated, with no or negligible reported side effects.
  • CCC is effective in reducing pain and sleep disturbance in patients with motor neurone disease related central neuropathic pain and is well tolerated.
  • a single-centre, 5-week (1-week run-in, 4-week treatment), randomized, double-blind, placebo-controlled, parallel-group trial is held for 20 patients having chronic anxiety of a composition of the invention (CCC), containing delta-9- tetrahydrocannabinol:cannabidiol (THC:CBD) delivered via an oil in clear gel-capsule of 1 ml, as adjunctive analgesic treatment.
  • CCC composition of the invention
  • THC:CBD delta-9- tetrahydrocannabinol:cannabidiol
  • Each capsule delivers 0.130 percent by volume of THC, THC Acid cannabinoid at 0.05-0.1 percent by volume, alpha-pinene at 0.21% percent by volume and beta-pinene, at 0.05% percent by volume.
  • Patients can gradually self-titrate to a maximum of 12 tablets in 24 hours.
  • CCC is effective in reducing anxiety and sleep disturbance in patients with chronic anxiety central neuropathic pain and is well tolerated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions comprenant des cannabinoïdes, en particulier CBD et Δ9-THC et leurs dérivés d'acide et des procédés pour le traitement de la douleur et de l'anxiété mettant en oeuvre les compositions.
PCT/AU2020/050436 2019-05-01 2020-05-01 Compositions et procédés pour le soulagement de la douleur et de l'anxiété WO2020220092A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020264426A AU2020264426A1 (en) 2019-05-01 2020-05-01 Compositions and methods for pain and anxiety relief

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2019901486A AU2019901486A0 (en) 2019-05-01 Compositions and Methods for Pain and Anxiety Relief
AU2019901486 2019-05-01

Publications (1)

Publication Number Publication Date
WO2020220092A1 true WO2020220092A1 (fr) 2020-11-05

Family

ID=73029220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2020/050436 WO2020220092A1 (fr) 2019-05-01 2020-05-01 Compositions et procédés pour le soulagement de la douleur et de l'anxiété

Country Status (2)

Country Link
AU (1) AU2020264426A1 (fr)
WO (1) WO2020220092A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220104542A (ko) * 2021-01-18 2022-07-26 주식회사 네이처센스 대마 추출물을 유효성분으로 포함하는 통증 완화 및 스트레스 관련 질환 예방 및 개선용 조성물
WO2023034568A1 (fr) * 2021-09-03 2023-03-09 Yale University Doses médicales thérapeutiques spécifiques de marijuana contre le stress et la douleur
WO2023056303A1 (fr) * 2021-09-28 2023-04-06 Gbs Global Biopharma, Inc. Formulations contenant des cannabinoïdes pour des troubles du mouvement parkinsoniens
US11666544B1 (en) * 2022-07-05 2023-06-06 Poviva Corp. Compositions and methods for treating hypertension
US11826342B1 (en) 2022-09-27 2023-11-28 Saaransh Mahna Cannabidiol formulation for alleviating pain and a method of manufacturing
WO2024054462A1 (fr) * 2022-09-05 2024-03-14 Gbs Global Biopharma, Inc. Formulations phytochimiques pour le traitement du stress et de l'anxiété
US12016829B2 (en) 2021-04-08 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007148094A1 (fr) * 2006-06-23 2007-12-27 Gw Pharma Limited Cannabinoïdes destinés à être utilisés dans le traitement de la douleur névropathique
WO2009004302A1 (fr) * 2007-07-05 2009-01-08 Gw Pharma Limited Utilisation de tétrahydrocannabinol et/ou du cannabidiol pour le traitement d'une maladie inflammatoire de l'intestin
WO2015200864A1 (fr) * 2014-06-27 2015-12-30 Crowley Kenton L Formulations de cannabinoïde buccale et sublinguale, et leur procédé de fabrication
WO2016064987A1 (fr) * 2014-10-21 2016-04-28 United Cannabis Corp. Extraits de cannabis et procédés de préparation et d'utilisation
WO2016181394A1 (fr) * 2015-05-13 2016-11-17 One World Cannabis Ltd Utilisation du cannabis pour traiter la fibromyalgie, méthodes et compositions associées
WO2019030762A2 (fr) * 2017-08-09 2019-02-14 Stahl Veronica Cannabis et ses dérivés pour le traitement de la douleur et de l'inflammation associées à la pulpe dentaire et de la régénération osseuse associée à des défauts osseux de la mâchoire
WO2019036243A1 (fr) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007148094A1 (fr) * 2006-06-23 2007-12-27 Gw Pharma Limited Cannabinoïdes destinés à être utilisés dans le traitement de la douleur névropathique
WO2009004302A1 (fr) * 2007-07-05 2009-01-08 Gw Pharma Limited Utilisation de tétrahydrocannabinol et/ou du cannabidiol pour le traitement d'une maladie inflammatoire de l'intestin
WO2015200864A1 (fr) * 2014-06-27 2015-12-30 Crowley Kenton L Formulations de cannabinoïde buccale et sublinguale, et leur procédé de fabrication
WO2016064987A1 (fr) * 2014-10-21 2016-04-28 United Cannabis Corp. Extraits de cannabis et procédés de préparation et d'utilisation
WO2016181394A1 (fr) * 2015-05-13 2016-11-17 One World Cannabis Ltd Utilisation du cannabis pour traiter la fibromyalgie, méthodes et compositions associées
WO2019030762A2 (fr) * 2017-08-09 2019-02-14 Stahl Veronica Cannabis et ses dérivés pour le traitement de la douleur et de l'inflammation associées à la pulpe dentaire et de la régénération osseuse associée à des défauts osseux de la mâchoire
WO2019036243A1 (fr) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARON, E.P. ET AL.: "Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort", THE JOURNAL OF HEADACHE AND PAIN, vol. 19, no. 37, 24 May 2018 (2018-05-24), XP021256738, DOI: 10. 1 186/s 10194-018-0862-2 *
BHATTACHRARYYA, SAGNIK, EGERTON ALICE, KIM EUITAE, ROSSO LULA, RIANO BARROS DANIELA, HAMMERS ALEXANDER, BRAMMER MICHAEL, TURKHEIME: "Acute induction of anxiety in humans by delta-9- tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors", SCIENTIFIC REPORTS, vol. 7, no. 15025, 3 November 2017 (2017-11-03), pages 1 - 15, XP055758240, DOI: 10.1038/s41598-017-14203-4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220104542A (ko) * 2021-01-18 2022-07-26 주식회사 네이처센스 대마 추출물을 유효성분으로 포함하는 통증 완화 및 스트레스 관련 질환 예방 및 개선용 조성물
KR102489407B1 (ko) * 2021-01-18 2023-01-17 주식회사 네이처센스 대마 추출물을 유효성분으로 포함하는 통증 완화 및 스트레스 관련 질환 예방 및 개선용 조성물
US12016829B2 (en) 2021-04-08 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
WO2023034568A1 (fr) * 2021-09-03 2023-03-09 Yale University Doses médicales thérapeutiques spécifiques de marijuana contre le stress et la douleur
WO2023056303A1 (fr) * 2021-09-28 2023-04-06 Gbs Global Biopharma, Inc. Formulations contenant des cannabinoïdes pour des troubles du mouvement parkinsoniens
US11666544B1 (en) * 2022-07-05 2023-06-06 Poviva Corp. Compositions and methods for treating hypertension
WO2024054462A1 (fr) * 2022-09-05 2024-03-14 Gbs Global Biopharma, Inc. Formulations phytochimiques pour le traitement du stress et de l'anxiété
US11826342B1 (en) 2022-09-27 2023-11-28 Saaransh Mahna Cannabidiol formulation for alleviating pain and a method of manufacturing

Also Published As

Publication number Publication date
AU2020264426A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
WO2020220092A1 (fr) Compositions et procédés pour le soulagement de la douleur et de l'anxiété
AU2018217273B2 (en) Phytocannabinoids in the treatment of cancer
Fine et al. The endocannabinoid system, cannabinoids, and pain
CA2656698C (fr) Cannabinoides destines a etre utilises dans le traitement de la douleur nevropathique
US8771760B2 (en) Method for the treatment of constipation
Costa On the pharmacological properties of Δ9‐tetrahydrocannabinol (THC)
US20220218650A1 (en) Composition and method for treating pain
AU2018100928A4 (en) Composition and method for opioid sparing
US11235014B2 (en) Herbal composition for the treatment of headache
US20220331287A1 (en) Compounds comprising cannabinoids and other natural ingredients for alieving premenstrual, menstrual and menopausal symptoms
AU2020412501A1 (en) Compositions comprising terpenes and their use in the treatment or alleviation of pain or anxiety
US20230138974A1 (en) Polyherbal Self Micro-Emulsifying Delivery System (SMEDS) composition for multi-disease treatment
US20220218649A1 (en) Composition for treating opioid withdrawal and method of manufacture
AU2021215262B2 (en) Composition and method for treating chronic pain
WO2020115751A1 (fr) Compositions à base de cannabis pour le traitement de la maladie d'alzheimer et de la démence
WO2021016612A1 (fr) Médicament enrobé de chanvre ou d'un autre cannabinoïde
von Fraunhofer Neurological and Health Benefits of Cannabidiol (CBD)
WO2024015780A1 (fr) Zlt-007 et méthodes de traitement de la neuropathie diabétique
Mandici et al. Cannabis therapy in neurological disorders: Recent advances and perspectives
Choudhury Pharmacological and Therapeutical Aspects of Cannabis
WO2023250274A1 (fr) Matrice de capture et de dissolution améliorée pour cannabinoïdes et leurs procédés de fabrication

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20798623

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020264426

Country of ref document: AU

Date of ref document: 20200501

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 20798623

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 12.04.2022)

122 Ep: pct application non-entry in european phase

Ref document number: 20798623

Country of ref document: EP

Kind code of ref document: A1